CA2384358A1 - Adn codant pour un recepteur humain de l'hormone de concentration de la melanine (mch1) et ses applications - Google Patents
Adn codant pour un recepteur humain de l'hormone de concentration de la melanine (mch1) et ses applications Download PDFInfo
- Publication number
- CA2384358A1 CA2384358A1 CA002384358A CA2384358A CA2384358A1 CA 2384358 A1 CA2384358 A1 CA 2384358A1 CA 002384358 A CA002384358 A CA 002384358A CA 2384358 A CA2384358 A CA 2384358A CA 2384358 A1 CA2384358 A1 CA 2384358A1
- Authority
- CA
- Canada
- Prior art keywords
- mch1 receptor
- human
- receptor
- chemical compound
- mch1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
L'invention concerne un acide nucléique isolé codant pour un récepteur humain de MCH1, un récepteur humain purifié de MCH1, des vecteurs contenant l'acide nucléique isolé codant pour un récepteur humain de MCH1, des cellules contenant ces vecteurs, des anticorps dirigés contre un récepteur humain de MCH1, des sondes d'acide nucléique servant à détecter l'acide nucléique codant pour les récepteurs humains de MCH1, des oligonucléotides antisens complémentaires des séquences uniques d'acide nucléique codant pour les récepteurs humains de MCH1, des animaux transgéniques non humains qui expriment l'ADN codant pour un récepteur humain de MCH1 normal ou mutant, des procédés d'isolement d'un récepteur humain de MCH1, des procédés permettant de traiter une anomalie liée à l'activité d'un récepteur humain de MCH1, ainsi que des procédés permettant de déterminer la liaison de composés à des récepteurs mammifères de MCH1. L'invention concerne un procédé visant à modifier le comportement alimentaire d'un sujet, ce procédé comportant l'administration au sujet d'une quantité efficace d'un antagoniste de MCH1 pour réduire la masse corporelle du sujet et/ou de réduire la consommation alimentaire du sujet. L'invention concerne en outre un procédé destiné à traiter un sujet atteint de dépression et/ou d'anxiété, qui comporte l'administration au sujet d'une quantité efficace d'un antagoniste de MCH1 pour traiter la dépression et/ou l'anxiété de celui-ci.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61063500A | 2000-07-05 | 2000-07-05 | |
US09/610,635 | 2000-07-05 | ||
PCT/US2001/021350 WO2002002744A2 (fr) | 2000-07-05 | 2001-07-05 | Adn codant pour un recepteur humain de l'hormone de concentration de la melanine (mch1) et ses applications |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2384358A1 true CA2384358A1 (fr) | 2002-01-10 |
Family
ID=24445829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002384358A Abandoned CA2384358A1 (fr) | 2000-07-05 | 2001-07-05 | Adn codant pour un recepteur humain de l'hormone de concentration de la melanine (mch1) et ses applications |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1246847A2 (fr) |
JP (1) | JP2004502423A (fr) |
AU (1) | AU7320701A (fr) |
CA (1) | CA2384358A1 (fr) |
WO (1) | WO2002002744A2 (fr) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221613B1 (en) | 1998-12-31 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof |
JP2004516239A (ja) | 2000-07-06 | 2004-06-03 | ニューロジェン コーポレイション | メラニン凝集ホルモン受容体リガンド |
US7078187B2 (en) | 2001-04-19 | 2006-07-18 | Neurogen Corporation | Melanin concentrating hormone receptors |
US7078484B2 (en) | 2001-04-19 | 2006-07-18 | Neurogen Corporation | Melanin concentrating hormone receptors |
US6809104B2 (en) | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
EP1392298B1 (fr) | 2001-05-04 | 2009-02-18 | Amgen Inc. | Composes heterocycliques fondus |
MXPA03010612A (es) | 2001-05-22 | 2004-04-02 | Neurogen Corp | Ligandos receptores de la hormona concentradora de melanina: analogos de 1-bencil-4-aril piperazina substiruidos. |
US7199135B2 (en) | 2001-07-05 | 2007-04-03 | H. Lundbeck A/S | Substituted alkyl amido piperidines |
US7105544B2 (en) * | 2001-07-05 | 2006-09-12 | Synaptic Pharmaceutical Corporation | Substituted alkyl amido piperidines |
US6727264B1 (en) | 2001-07-05 | 2004-04-27 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as MCH selective antagonists |
HUP0401880A2 (hu) * | 2001-07-05 | 2005-01-28 | Synaptic Pharmaceutical Corporation | Helyettesített anilin-piperidinek mint MCH-szelektív antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
JP2005526709A (ja) | 2002-01-10 | 2005-09-08 | ニューロジェン・コーポレーション | メラニン凝集ホルモン受容体リガンド:置換ベンゾイミダゾールアナログ |
US7160879B2 (en) | 2002-01-10 | 2007-01-09 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues |
UA77814C2 (en) | 2002-07-03 | 2007-01-15 | Lundbeck & Co As H | Spirocyclic piperidines as antagonists of mch1 and use thereof |
UA77536C2 (en) * | 2002-07-03 | 2006-12-15 | Lundbeck & Co As H | Secondary aminoaniline piperidines as mch1 antagonists and their use |
EP1553089B1 (fr) | 2002-07-30 | 2009-09-30 | Banyu Pharmaceutical Co., Ltd. | Antagoniste de recepteur d'hormone concentrant de la melanine comprenant un derive de benzimidazole en tant qu'ingredient actif |
AU2003262020A1 (en) * | 2002-09-10 | 2004-04-30 | Takeda Pharmaceutical Company Limited | Human slt transgenic animal |
KR20050103184A (ko) | 2002-11-06 | 2005-10-27 | 암젠 인코포레이션 | 융합된 헤테로사이클릭 화합물들 |
CA2515717A1 (fr) | 2003-02-10 | 2004-08-19 | Banyu Pharmaceutical Co., Ltd. | Antagonistes des recepteurs de l'hormone concentrant la melanine contenant des derives de piperidine en tant que principe actif |
JP4552854B2 (ja) | 2003-05-21 | 2010-09-29 | 萬有製薬株式会社 | 2−アミノキノリン誘導体 |
US7319108B2 (en) | 2004-01-25 | 2008-01-15 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted heterocycles, process for their preparation and their use as medicaments |
US7241787B2 (en) | 2004-01-25 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments |
CN1930126A (zh) | 2004-03-05 | 2007-03-14 | 万有制药株式会社 | 吡啶酮衍生物 |
DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2007018248A1 (fr) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Composé de pyridone |
DE602006017712D1 (de) | 2005-08-24 | 2010-12-02 | Banyu Pharma Co Ltd | Phenylpyridonderivat |
US20090264426A1 (en) | 2005-09-07 | 2009-10-22 | Shunji Sakuraba | Bicyclic aromatic substituted pyridone derivative |
EP1987006B1 (fr) | 2006-02-15 | 2011-01-12 | Sanofi-Aventis | Nouvelles aryldihydroisoquinolinones a substitution amino-alcool, procede pour les preparer et leur utilisation en tant que medicaments |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
WO2010003624A2 (fr) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation |
WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
AR075402A1 (es) | 2009-02-13 | 2011-03-30 | Sanofi Aventis | Derivados heterociclicos oxigenados y/o nitrogenados de tetrahidronaftaleno, medicamentos que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad,entre otros. |
TW201040154A (en) | 2009-02-13 | 2010-11-16 | Sanofi Aventis | Novel substituted indanes, process for preparation thereof and use thereof as a medicament |
WO2011023754A1 (fr) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, substances pharmaceutiques comprenant ces composés et leur utilisation |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
EP2683704B1 (fr) | 2011-03-08 | 2014-12-17 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
EP2683702B1 (fr) | 2011-03-08 | 2014-12-24 | Sanofi | Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation |
EP2683699B1 (fr) | 2011-03-08 | 2015-06-24 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120054A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120051A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683701B1 (fr) | 2011-03-08 | 2014-12-24 | Sanofi | Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0848060A3 (fr) * | 1996-12-11 | 2000-02-02 | Smithkline Beecham Corporation | Variante d'épissure de 11CB humaine |
US7198910B1 (en) * | 1999-07-14 | 2007-04-03 | Merck & Co., Inc. | Nucleic acid encoding melanin-concentrating hormone receptor |
-
2001
- 2001-07-05 WO PCT/US2001/021350 patent/WO2002002744A2/fr not_active Application Discontinuation
- 2001-07-05 AU AU73207/01A patent/AU7320701A/en not_active Abandoned
- 2001-07-05 JP JP2002507986A patent/JP2004502423A/ja active Pending
- 2001-07-05 CA CA002384358A patent/CA2384358A1/fr not_active Abandoned
- 2001-07-05 EP EP01952456A patent/EP1246847A2/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU7320701A (en) | 2002-01-14 |
WO2002002744A3 (fr) | 2002-08-08 |
EP1246847A2 (fr) | 2002-10-09 |
JP2004502423A (ja) | 2004-01-29 |
WO2002002744A2 (fr) | 2002-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2384358A1 (fr) | Adn codant pour un recepteur humain de l'hormone de concentration de la melanine (mch1) et ses applications | |
US6720324B2 (en) | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | |
AU783403B2 (en) | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | |
AU774398B2 (en) | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | |
EP1075493B1 (fr) | Adn codant le recepteur snorf25 | |
US6727264B1 (en) | Substituted anilinic piperidines as MCH selective antagonists | |
EP1531816B1 (fr) | Piperidines spirocycliques utilisees comme antagonistes des mch1 et utilisations associees | |
KR20040027870A (ko) | Mch 선택적인 안타고니스트로서의 치환 아닐린 피페리딘 | |
US7105544B2 (en) | Substituted alkyl amido piperidines | |
US20040038855A1 (en) | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | |
US7374895B2 (en) | Guanosine triphosphate (GTP) binding protein-coupled receptor proteins that bind histamine and are expressed in the brain | |
US20030077701A1 (en) | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | |
US7473698B2 (en) | Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof | |
US7199135B2 (en) | Substituted alkyl amido piperidines | |
AU2006200052A1 (en) | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |